McKesson Splits CEO Into Operations & Strategy: Hammergren & Mahoney
Executive Summary
McKessonHBOC is relying on two young McKesson execs acting as a two-person CEO office to drive the integration of distribution and information businesses into a company able to link each episode of care from first patient contact to prescription dispensing.
You may also be interested in...
Ex McKesson CEO named Quidel chairman
Former Sandoz Pharma and McKesson CEO Mark Pulido has been named chairman of Quidel, the diagnostics firm announced June 2. Pulido, 51, has been a director of Quidel for two years and was most recently chairman and CEO of BenefitPoint, Inc. Pulido resigned as head of McKesson in 1999 following the disclosure of reporting irregularities associated with the wholesaler's merger with the health information firm HBOC (1"The Pink Sheet" June 28, 1999, p. 6)...
Ex McKesson CEO named Quidel chairman
Former Sandoz Pharma and McKesson CEO Mark Pulido has been named chairman of Quidel, the diagnostics firm announced June 2. Pulido, 51, has been a director of Quidel for two years and was most recently chairman and CEO of BenefitPoint, Inc. Pulido resigned as head of McKesson in 1999 following the disclosure of reporting irregularities associated with the wholesaler's merger with the health information firm HBOC (1"The Pink Sheet" June 28, 1999, p. 6)...
BIO Gets Pep Talk From Commander-In-Chief; Is Boom-And-Bust Cycle Over?
The recent rebound in the biotechnology sector is "for real," FDA Commissioner McClellan declared during the Biotechnology Industry Organization annual meeting in Washington, D.C. June 23